Trial Profile

A phase III randomized trial for the treatment of newly diagnosed supratentorial PNET and high risk medulloblastoma in children less than 36 months old with intensive induction chemotherapy with methotrexate followed by consolidation with stem cell rescue versus the same therapy without methotrexate.

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carboplatin; Cisplatin; Cyclophosphamide; Etoposide; Filgrastim; Folinic acid; Folinic acid; Methotrexate; Thiotepa; Vincristine
Indications Brain cancer; Medulloblastoma
Focus Biomarker; Pharmacogenomic; Therapeutic Use

08 Jun 2021 Biomarkers information updated
25 Aug 2012 New source identified and integrated (M.D. Anderson Cancer Center, 2012-0174).
25 Aug 2012 Planned number of patients changed from 96 to 152 as reported by M.D. Anderson Cancer Center record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com